# Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

> **NCT06784752** · PHASE3 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 240 (estimated)

## Conditions studied

- Somatostatin Receptor Positive (SSTR+)
- Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

## Interventions

- **RADIATION:** [177Lu]Lu-DOTA-TATE
- **DRUG:** Octreotide LAR

## Key facts

- **NCT ID:** NCT06784752
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-30
- **Primary completion:** 2028-12-08
- **Final completion:** 2034-01-23
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06784752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06784752, "Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06784752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*